viewPropanc Biopharma, Inc.

Propanc poised to unlock shareholder value as it boosts its patent portfolio for cancer-fighting drugs

The biopharmaceutical company now has 65 patents either in force or pending in most major countries around the globe covering its lead drug candidate PRP

woman looking at sample
Propanc is developing a long-term therapy to prevent tumor recurrence and metastasis

Propanc Biopharma Inc (OTCMTKS:PPCBD) has boosted its intellectual property portfolio for its anti-cancer technology currently in development, the company announced on Thursday.

The biopharmaceutical company’s portfolio now has 65 patents either in force or pending in most major countries around the globe.

Over the past year, three additional patent families have entered the national sphere, where a patent application is filed in individual countries to achieve grant status.

READ: Propanc Biopharma taps longtime advisor as chief financial officer

Founded in 2007, Propanc develops new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. In the last 10 years, the Mebourne, Australia-based company has uncovered evidence to suggest that pancreatic enzymes basically assist with cell-to-cell contact and communication and can be used to halt the spread of cancer.

“Our IP portfolio is a world leader in the field of administration of proenzymes for the treatment and prevention of metastatic cancer, said Dr Julian Kenyon, Propanc’s Chief Scientific Officer.

"IP is the cornerstone of any biotech company, and places us in a strong position to unlock significant value, as we plan to progress into a First-In-Human study and then hopefully towards proof of concept in a specific cancer indication, where we will then look at possible licensing opportunities.”

Propanc is developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis.

The pharma company’s lead drug candidate, PRP, has four patent families to cover the use of proenzymes for treating cancer either individually or through a mix of trypsinogen and chymotrypsinogen pancreatic proenzymes.

“We are firmly of the opinion that our current market value does not truly reflect the advancement of our lead product, PRP, or its true potential as a breakthrough, long term treatment for aggressive and fast spreading cancers from solid tumors by targeting and eradicating cancer stem cells,” Kenyon said in a statement.

Shares of Propanc climbed 31.2% on OTC markets on Thursday to reach US$3.40.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Propanc Biopharma, Inc.

Price: 0.0022 USD

Market: OTCQB
Market Cap: $1.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Pan Asia Metals says drilling at Khao Soon Tungsten project is going well

Pan Asia Metals Limited's (ASX:PAM) Paul Lock caught up with Proactive's Andrew Scott soon after announcing they've been formally awarded Special Prospecting Licence TSPL 2/2563 for the Khao Soon Tungsten Project in Thailand. It's a wolframite style tungsten project about 600 kilometres south of...

6 hours, 2 minutes ago

2 min read